BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36148710)

  • 1. Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen.
    Loren G; Espuny I; Llorente A; Donoghue C; Verdaguer X; Gomis RR; Riera A
    Eur J Med Chem; 2022 Dec; 243():114770. PubMed ID: 36148710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
    Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
    J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.
    Cyrus K; Wehenkel M; Choi EY; Lee H; Swanson H; Kim KB
    ChemMedChem; 2010 Jul; 5(7):979-85. PubMed ID: 20512796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders.
    Roberts BL; Ma ZX; Gao A; Leisten ED; Yin D; Xu W; Tang W
    ACS Chem Biol; 2020 Jun; 15(6):1487-1496. PubMed ID: 32255606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
    Hu J; Hu B; Wang M; Xu F; Miao B; Yang CY; Wang M; Liu Z; Hayes DF; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
    J Med Chem; 2019 Feb; 62(3):1420-1442. PubMed ID: 30990042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders.
    Luo G; Li X; Lin X; Lu X; Li Z; Xiang H
    J Steroid Biochem Mol Biol; 2022 Oct; 223():106154. PubMed ID: 35870675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
    Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P
    ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
    Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
    J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.
    Smalley JP; Baker IM; Pytel WA; Lin LY; Bowman KJ; Schwabe JWR; Cowley SM; Hodgkinson JT
    J Med Chem; 2022 Apr; 65(7):5642-5659. PubMed ID: 35293758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
    Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.
    Hayhow TG; Williamson B; Lawson M; Cureton N; Braybrooke EL; Campbell A; Carbajo RJ; Cheraghchi-Bashi A; Chiarparin E; Diène CR; Fallan C; Fisher DI; Goldberg FW; Hopcroft L; Hopcroft P; Jackson A; Kettle JG; Klinowska T; Künzel U; Lamont G; Lewis HJ; Maglennon G; Martin S; Gutierrez PM; Morrow CJ; Nikolaou M; Nissink JWM; O'Shea P; Polanski R; Schade M; Scott JS; Smith A; Weber J; Wilson J; Yang B; Crafter C
    Commun Biol; 2024 May; 7(1):563. PubMed ID: 38740899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of visible-light-activatable photocaged PROTACs.
    Weng W; Xue G; Pan Z
    Eur J Med Chem; 2024 Feb; 265():116062. PubMed ID: 38128235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.
    Crew AP; Raina K; Dong H; Qian Y; Wang J; Vigil D; Serebrenik YV; Hamman BD; Morgan A; Ferraro C; Siu K; Neklesa TK; Winkler JD; Coleman KG; Crews CM
    J Med Chem; 2018 Jan; 61(2):583-598. PubMed ID: 28692295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
    Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
    J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of VHL-recruiting STING PROTACs that suppress innate immunity.
    Zhu Z; Johnson RL; Zhang Z; Herring LE; Jiang G; Damania B; James LI; Liu P
    Cell Mol Life Sci; 2023 May; 80(6):149. PubMed ID: 37183204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins.
    Ng YLD; Bricelj A; Jansen JA; Murgai A; Peter K; Donovan KA; Gütschow M; Krönke J; Steinebach C; Sosič I
    J Med Chem; 2023 Apr; 66(7):4703-4733. PubMed ID: 36996313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.